

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019

<https://marketpublishers.com/r/ED09467B2094EN.html>

Date: November 2019

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: ED09467B2094EN

Abstracts

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019

SUMMARY

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019, outlays comprehensive information on the E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - E3 Ubiquitin-Protein Ligase X-linked inhibitor of apoptosis protein (XIAP) also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4) is a protein that stops apoptotic cell death. It modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. It acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. It inactivates CASP9 by keeping it in inactive state.

It regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. It acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). The molecules developed by companies in Phase II and Preclinical stages are 4 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Cervical Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Head And Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma and Soft Tissue Sarcoma.

Furthermore, this report also reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for E3

Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

The report assesses E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Overview

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development

Adamed Sp zoo

Ascenta Therapeutics Inc

Astex Pharmaceuticals Inc

Canget BioTekpharma LLC

Novartis AG

Noxopharm Ltd

Takeda Pharmaceutical Co Ltd

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles

ADO-532 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTX-660 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idronoxil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit XIAP for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-3256336 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Products

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis

Protein or XIAP or EC 6.3.2.) - Product Development Milestones

Featured News & Press Releases

Nov 12, 2019: Noxopharm: DARRT-1 interim data presented to conference

Nov 12, 2019: Noxopharm: LuPIN data being presented to conference

Oct 21, 2019: Noxopharm: Durable anti-cancer effect confirmed in DARRT-1 study

Oct 10, 2019: Debiopharm begins enrolment in CATRIPCA trial

Sep 30, 2019: Further data review shows major clinical benefits from Veyonda

Sep 30, 2019: Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding phase II results for high-risk Head and Neck Cancer patients

Sep 17, 2019: Veyonda and radiotherapy profiled at key oncology meeting

Sep 03, 2019: Debiopharm successfully completes randomized phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

Aug 28, 2019: Veyonda enhances radiotherapy in prostate cancer treatment further promising results

Aug 21, 2019: Noxopharm: Pre-clinical evidence confirms Veyonda abscopal effect

Jul 19, 2019: Noxopharm provides update on DARRT-1 and LuPIN studies

Jul 02, 2019: LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019

Jun 26, 2019: Conference hears of positive interim data from LuPIN trial

May 30, 2019: Noxopharm announces its DARRT-1 study fully enrolled

May 21, 2019: Debiopharm expands its immuno-oncology development program for Debio 1143, with the first IAP inhibitor/Nivolumab combination trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adamed Sp zoo, H2 2019
Pipeline by Ascenta Therapeutics Inc, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by Canget BioTekpharma LLC, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Noxopharm Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Adamed Sp zoo

Ascenta Therapeutics Inc

Astex Pharmaceuticals Inc

Canget BioTekpharma LLC

Novartis AG

Noxopharm Ltd

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/ED09467B2094EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ED09467B2094EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970